FDA Grants Priority Review to Pfizer and Astellas’ Xtandi for High-Risk Prostate Cancer
The US Food and Drug Administration (FDA) has granted priority review status to the submission...
NYSE: PFE
Pfizer’s RSV Vaccine Abrysvo Receives FDA Authorization for Maternal Immunization
The US Food and Drug Administration (FDA) has authorized the use of Pfizer’s (NYSE: PFE)...
GSK’s RSV Vaccine Arexvy Launches in US Pharmacies Ahead of 2023/24 Season
GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has announced that its respiratory syncytial virus...
Seagen’s Tukysa Meets Primary Endpoint in Phase III Study for HER2+ Breast Cancer
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...
Pfizer’s Elrexfio Earns Accelerated FDA Approval for Relapsed/Refractory Multiple Myeloma
This week, Pfizer (NYSE: PFE) received an accelerated approval from the US Food and Drug...
Pfizer Faces Whistleblower Lawsuit Over Alleged FCPA Violations in China
A former employee of Pfizer Inc., (NYSE: PFE), Frank Han, has filed a civil lawsuit...
GSK Files Patent Infringement Lawsuit Against Pfizer’s RSV Vaccine Abrysvo
UK pharmaceutical giant GlaxoSmithKline (NYSE: GSK) has taken US-based Pfizer Inc., (NYSE: PFE) to court,...
Pfizer Inc. Reports Q2 2023 Revenues, Signals Shift Beyond COVID-19 Products
US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the second...
AstraZeneca’s Alexion Secures Gene Therapy Portfolio in Deal with Pfizer
AstraZeneca’s rare disease unit, Alexion (AZ, NASDAQ: AZN), has signed a significant purchase and license...
Pfizer Announces Leadership Shake-Up with Focus on Oncology R&D
Pfizer Inc., (NYSE: PFE) has announced significant changes in its Research and Development (R&D) leadership....
Pfizer Ends Partnership with Syros Pharmaceuticals for Sickle Cell Disease Program
Syros Pharmaceuticals Inc., (NASDAQ: SYRS) has disclosed in an SEC filing that Pfizer (NYSE: PFE)...
Riparian Pharmaceuticals Secures Exclusive License Agreement with Pfizer for Cardiovascular Program
US-based Riparian Pharmaceuticals, Inc., a biotechnology company focused on cardiovascular diseases and co-incubated by Viva...
Pfizer’s GBS Vaccine Candidate GBS6 Shows Promise in Phase II Maternal Immunization Study
Pfizer (NYSE: PFE) has this week published the Phase II data for its Group B...
Pfizer and Flagship Pioneering Invest $100 Million in Drug Candidates Development
Global pharmaceutical giant Pfizer (NYSE: PFE) and venture capital firm Flagship Pioneering have this week...
Pfizer Launches Phase III Trial for Quadrivalent Influenza modRNA Vaccine in Argentina
Global pharmaceutical giant Pfizer (NYSE: PFE) has commenced recruitment in Argentina for a Phase III...
Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential
Shanghai Circode Bio has entered into a partnership with US pharmaceutical giant Pfizer (NYSE: PFE)...
China’s MofCOM Hosts Symposium with Multinational Corporations, Promises Development Opportunities
This week, China’s Ministry of Commerce (MofCOM) convened a symposium attended by representatives from a...
Pfizer Partners with CSPC Pharmaceutical to Localize Paxlovid in China
US pharmaceutical major Pfizer (NYSE: PFE) has entered into a partnership with China-based CSPC Pharmaceutical...
Pfizer’s Prevenar 13 Receives Expanded Age Range Approval in China
U.S.-based pharmaceutical giant Pfizer (NYSE: PFE) has reported receiving an additional indication approval from the...
Pfizer and Sinopharm Expand Partnership to Enhance Drug Distribution and Lifecycle Solutions
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced a strategic partnership with China-based Sinopharm...